科伦药业(002422.SZ)：罗替高汀贴片获得药品注册批准

Core Viewpoint - Kelun Pharmaceutical has received approval from the National Medical Products Administration for its transdermal patch "Rotigotine Patch," which is the world's first transdermal patch for treating Parkinson's disease, particularly for early-onset patients [1] Company Summary - The Rotigotine Patch is recognized as one of the first-line medications for early-stage Parkinson's disease [1] - Compared to oral medications, the transdermal patch reduces gastrointestinal adverse reactions, avoids fluctuations in blood drug concentration, and minimizes motor symptom variability, thereby enhancing patient safety and compliance [1]